Aug 2026· Toxicon· Vol 283, pp.
109268
· 0 citations· 207 references
Medicine
TL;DR
Overall, the available evidence indicates that effective snakebite management in Brazil requires addressing the combined challenges posed by venom variability and current antivenom programs, optimizing antivenom design and coverage, expanding equitable access to healthcare, promoting evidence-based community education, and encouraging the scientific evaluation of safe complementary practices.
Abstract
Snakebite envenoming (SBE) remains a significant public health issue in Brazil, where venom diversity, barriers to timely healthcare, and widespread ethnomedical practices intersect. Venom variability across medically relevant snake species poses important challenges for antivenom design and antigenic coverage in the country. In this context, an integrative review was conducted to examine how venom diversity, antivenom efficacy and protective coverage, and traditional first aid and pre-hospital practices influence the management of snakebite envenoming. Preclinical studies revealed substantial inter- and intraspecific variation in the venoms of Bothrops, Crotalus, Lachesis, and Micrurus species, resulting in heterogeneous venom profiles and biological activities, including lethality that may affect antigenic recognition and neutralization. Although Brazilian antivenoms generally neutralize major toxic activities and reverse life-threatening systemic manifestations of envenoming, there are important limitations in their protective capacity against well-established severe complications such as local tissue damage and neurological syndromes. These limitations are highlighted by the incomplete representation of regional venom diversity in immunization pools and differential toxin immunorecognition. Delayed access to antivenom further worsens clinical outcomes, particularly in remote areas. Concurrently, medicinal plants and first aid and pre-hospital practices were widely used despite limited scientific validation and, in some cases, potential iatrogenic risks to human health. Overall, the available evidence indicates that effective snakebite management in Brazil requires addressing the combined challenges posed by venom variability and current antivenom programs, optimizing antivenom design and coverage, expanding equitable access to healthcare, promoting evidence-based community education, and encouraging the scientific evaluation of safe complementary practices.
Clinical evidence from two clinical studies in patients with SBE supports further evaluation of varespladib as an in-hospital treatment administered, with encouraging signals from Agkistrodon contortrix (copperhead), Micrurus fulvius (eastern coral snake), and Bungarus spp (krait).
Madison McGann, T. Platts-Mills, C. Gerardo· Expert Opinion on Investigat...· 0 citations
The treatment of envenomation by venomous animals, snakes, and arthropods is based on the administration of specific antivenom serum. This serum must be used in the quantity indicated by regulations, as soon as possible after the envenomation, and by specialized medical personnel. Therefore, it is essential to ensure t...
César Augusto Bonilla Ferreyra· Diagnóstico· 0 citations
Venomous animals are considered one of the world's neglected diseases. Globally, it is estimated that between 1.8and 2.7 million cases of snakebite envenomation occur annually, with a mortality rate ranging from 81,000 to 138,000deaths. These incidents occur in low-income countries in Asia, Africa, and Latin America. I...
The carpet viper (Echis romani, recently separated from E. ocellatus) accounts for at least 66% of confirmed snakebite envenomings in the Nigerian savanna. Despite this, continental hazard modeling ranks it second in Nigeria. It is smaller and not necessarily more venomous per bite than the puff adder (Bitis arietans)...
G. Michael, A. A. Bala· Current Tropical Medicine Re...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.